Web Results

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. DR ...

search.rpxcorp.com/lit/njdce-332415-boehringer-ingelheim-pharmaceuticals-v-dr-reddy-s-laboratories

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. DR. REDDY'S LABORATORIES, LTD. et al. 3:16-cv-02394; Filed: 04/28/2016; Closed: 05/16/ ...

Boehringer Ingelheim Pharmaceuticals, Inc. | Federal Trade ...

www.ftc.gov/enforcement/cases-proceedings/091-0023/boehringer-ingelheim-pharmaceuticals-inc

Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir. ), Response of FTC to Petition for Rehearing En Banc (113.12 ...

Cognitive Function in Ambulatory Patients with Systolic Heart Failure ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0113447

Nov 26, 2014 ... ... and safety monitoring board and consulting fees from Boehringer Ingelheim; Dr . ... Dr. Graham reports owning stock in March Pharmaceuticals, Medtronic, and Pfizer ..... Watson Clinic Center for Research, Inc. (1): J. Gonzalez, and B. Donley; .... Kindermann I, Fischer D, Karbach J, Link A, Walenta K, et al.

Reduced risk of hypoglycemia with once-daily glargine versus twice ...

www.sciencedirect.com/science/article/pii/S1056872714001184

... of this analogue in reducing the risk of hypoglycemia (Bazzano et al., 2008). ..... Analysis of HbA1c-adjusted number needed to harm with NPH vs Glargine. ..... et al., 2001; J. Rosenstock, S.L. Schwartz, C.M. Clark Jr., G.D. Park, D.W. Donley, ... Johnson, Novartis and Boehringer Ingelheim, and Amylin Pharmaceuticals.

PDF (737 KB) - Endocrine Society Journals and Publications

press.endocrine.org/doi/pdf/10.1210/jc.2015-4181

Feb 10, 2016 ... (B.J.), Eli Lilly Canada Inc., Toronto, Ontario, Canada. 1354. Dempster et al ..... nosumab vs teriparatide group (P .001) at month 3 in all ..... research grants from Amgen, Boehringer Ingelheim, Immunodi- ... speaker for Alexion Pharmaceuticals and Radius Health. S.D.R. .... Ma YL, Zeng Q, Donley DW, et al.

Full Text - Learning & Memory - Cshlp.org

learnmem.cshlp.org/content/20/12/730.full

As part of the “extended amygdala” (Alheid and Heimer 1988; Alheid et al. .... ANOVA indicated a significant effect of Stress Level (i.e., before vs. after shock), F (1 .... meloxicam (Metacam, Boehringer Ingelheim) to reduce post-operative discomfort. ... was facilitated with 0.5 mg/kg atipamezole HCl (Antisedan, Orion Pharma).

Effectiveness and safety of different azacitidine dosage regimens in ...

www.sciencedirect.com/science/article/pii/S0145212614000666

AZA 5-2-2, p = 0.0021; AZA 5 vs. AZA 7, p ... Table 3. Assigned scores in lower- risk patients based on the prognostic score described by Garcia-Manero et al.

CGRP antagonist infused into the bed nucleus of the stria terminalis ...

learnmem.cshlp.org/content/20/12/730.full.pdf

et al. 2009), intra-BNST infusions of calcitonin gene-related pep- tide (CGRP) ... 2004; Donley et al. .... significant effect of Stress Level (i.e., before vs. after shock) ,. F(1,14) ..... dexmedetomidine HCl (Dexdomitor, Orion Pharma), and received ... Boehringer Ingelheim) to reduce post-operative discomfort. .... Glassbeads Inc.).

Insulin Therapy in Type 2 Diabetes Mellitus: A Practical Approach for ...

jaoa.org/article.aspx?articleid=2094449

Transition to Basal Insulin: Basal Insulin Analogs vs Human Insulin ..... may mirror a full basal bolus approach.<sup>59</sup> In a study by Raccah et al,<sup>59</sup> stepwise addition ... bureau for Novo Nordisk Inc, Boehringer Ingelheim Pharmaceuticals, Inc–Eli Lilly .... Rosenstock J, Schwartz SL, Clark CMJr, Park GD, Donley DW, Edwards MB.

PTAB.US: March 2012

www.ptab.us/2012_03_01_archive.html

Mar 30, 2012 ... 3656 Ex Parte 7757582 et al Ex parte SHIMANO, INC. ... Co. v. Avery Dennison Corp., 350 F.3d 1365, 1371 (Fed. Cir. ..... 2436 Ex Parte Donley et al 10/401,919 HUGHES 102(b) SHERIDAN .... 103(a) MICHAEL P. MORRIS BOEHRINGER INGELHEIM USA CORPORATION EXAMINER DESAI, RITA J

More Info

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC ...

search.rpxcorp.com

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC PHARM CO. , LTD. et al. 3:15-cv-05982; Filed: 08/04/2015; Case Updated Daily; Latest ...

Differential Effects of Teriparatide and Denosumab on Intact PTH ...

www.ncbi.nlm.nih.gov

Feb 10, 2016 ... Medical writing support was provided by Lori Kornberg (INC Research ... and is a consultant for Merck, Tarsa Pharmaceuticals, and Radius Health. ... from Amgen, Boehringer Ingelheim, Immunodiagnostics, Lilly, Merck, ... Cummings SR, San Martin J, McClung MR, et al. .... Ma YL, Zeng Q, Donley DW, et al.

A Randomized, Controlled, Pilot Study of Acamprosate Added to ...

www.ncbi.nlm.nih.gov

Comparisons between treatment arms (acamprosate vs placebo) were made by the .... Tiihonen et al found similar benefit in 62 alcoholic patients. ... served in advisory/consultative relationships with Boehringer Ingelheim and Pfizer. ... Inc, Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, Wyeth-Ayerst Laboratories.